Episode Details

Researchers are renewing efforts to find Alzheimer’s disease treatments that remove harmful proteins from the brain. Such vaccines could possibly offer an easier and lower-cost choice for millions of people, several scientists and industry leaders say. 

研究人员正在继续努力寻找消除大脑中有害蛋白质的阿尔茨海默病治疗方法。几位科学家和行业领袖表示，此类疫苗可能为数百万人提供更简单、成本更低的选择。 

The brain-wasting disease causes thinking and memory problems.

这种脑消耗性疾病会导致思维和记忆问题。 

The U.S. government website ClinicalTrials.gov shows that at least seven possible Alzheimer’s vaccines are in human testing or have completed such trials. The experimental treatments are designed to use the body’s natural defense system to destroy Alzheimer’s-linked proteins in the brain. The proteins are beta amyloid and tau. 

美国政府网站ClinicalTrials.gov显示，至少有七种可能的阿尔茨海默病疫苗正在进行人体测试或已经完成此类试验。这些实验性治疗旨在利用人体的自然防御系统来破坏大脑中与阿尔茨海默病相关的蛋白质。这些蛋白质是β淀粉样蛋白和tau蛋白。 

The renewed interest in Alzheimer’s vaccines follows a promising first attempt more than 20 years ago. That vaccine work halted after six percent of study volunteers developed a life-threatening brain condition called meningoencephalitis. 

继 20 多年前首次尝试后，人们对阿尔茨海默病疫苗重新产生了兴趣。在百分之六的研究志愿者患上一种名为脑膜脑炎的危及生命的脑部疾病后，疫苗工作停止了。 

Researchers then found a safer method using closely targeted synthetic antibodies in patients. These antibodies avoid extreme immune system reaction. 

研究人员随后找到了一种更安全的方法，在患者体内使用紧密靶向的合成抗体。这些抗体避免了极端的免疫系统反应。 

Health care companies Eisai and Biogen launched a new medication called Leqembi and health care company Eli Lilly launched Donanemab. American government drug experts are reviewing the treatments. 

医疗保健公司卫材 (Eisai) 和百健 (Biogen) 推出了一种名为 Leqembi 的新药，医疗保健公司礼来 (Eli Lilly) 推出了 Donanemab。美国政府药物专家正在审查这些治疗方法。 

Listen Now